Target intelligence / Profile preview

Shigella flexneri 2a O-antigen (Sf2a O-antigen) (Sf2a O-antigen)

Target
Sf2a O-antigen
Molecular classification
Bacterial surface antigen, Polysaccharide, Lipopolysaccharide component
01

Overview

The Shigella flexneri 2a O-antigen is a key polysaccharide component of the lipopolysaccharide (LPS) located on the outer membrane of Shigella flexneri serotype 2a, a major causative agent of bacillary dysentery (shigellosis) (1, 6). It is composed of a repeating tetrasaccharide unit consisting of rhamnose and N-acetylglucosamine residues, with specific glucose and O-acetyl modifications that determine its serological identity (4, 6). Biologically, the O-antigen is essential for bacterial virulence, providing resistance to the acidic environment of the stomach and protecting the pathogen from the host's innate immune system (8, 11). It is the primary target for vaccine-induced antibodies, which provide protection by neutralizing the bacteria and promoting complement-mediated killing (1, 2). Because natural immunity to Shigella is serotype-specific, this O-antigen is a critical antigen in the development of conjugate and bioconjugate vaccines, such as Flexyn2a and SF2a-TT (3, 9). These vaccines aim to elicit high titers of functional IgG and IgA antibodies to prevent infection and reduce the global burden of shigellosis, particularly in pediatric populations in developing countries (1, 3).

Other names
Shigella flexneri 2a O-polysaccharideSf2a O-SPShigella flexneri 2a O-specific polysaccharideSf2a OSPS. flexneri 2a LPS O-antigen
02

Mechanism of action

Induction of serotype-specific antibodies (IgG and IgA) that bind to the O-antigen, mediating complement-dependent bactericidal activity and preventing bacterial invasion of the colonic epithelium.

03

Biological functions

Immune evasionAcid resistanceSerotype specificityStructural integrity of the outer membrane
04

Disease associations

ShigellosisInfection
05

Safety considerations

Serotype-specific immunity (limited cross-protection against other Shigella serotypes)Potential for serotype conversion or switching to evade vaccine-induced immunityRequirement for multivalent vaccine formulations to achieve broad coverage
06

Interacting drugs

Flexyn2a

4 more in the full profile.

07

Biomarkers

Anti-Sf2a LPS IgG titerAnti-Sf2a LPS IgA titerSerum bactericidal activity (SBA)

Beyond the preview

Go deeper on Shigella flexneri 2a O-antigen (Sf2a O-antigen) (Sf2a O-antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella flexneri 2a O-antigen (Sf2a O-antigen) (Sf2a O-antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call